In the Skov3-ip1 and HeyA8 orthotopic models of ovarian cancer, they showed that the blockade of adrenergic signaling with the non-selective β-blocker propranolol or the β2-adrenergic receptor specific blocker terbutaline decreased levels of PTGS2 in tumor cells. Here, PTGS2 is linked to neoplasm.